Peptides and Weight Loss: What Actually Works, What Doesn't, and How to Think About It

Peptides and weight loss are now inseparably linked in the public conversation — and for good reason. The GLP-1 class has produced the most significant pharmacological weight loss results in clinical history. But that success has also created noise: research peptides marketed alongside approved drugs, mechanism claims that outrun the data, and patients asking practitioners about compounds that have zero human trials.

This guide cuts through that. Here’s the complete evidence landscape, tiered by what we actually know.

---

Quick Reference: Fat Burning Peptides Ranked

Compound	Mechanism	Evidence	Avg. Fat Loss	Legal Status
Tirzepatide	GLP-1/GIP agonist	Strong	~20% body weight	FDA-Approved
Semaglutide	GLP-1 agonist	Strong	~15–17% body weight	FDA-Approved
Tesamorelin	GHRH analog	Strong	15–20% visceral fat	FDA-Approved (narrow)
CJC-1295 / Ipamorelin	GHRH + GHRP	Moderate	Body composition change	Restricted
AOD-9604	GH fragment	Preliminary	Animal data only	Research-only
5-Amino-1MQ	NNMT inhibitor	Preliminary	Animal data only	Research-only

---

How Peptides Affect Weight: The Main Mechanisms

Peptides drive weight loss through several distinct biological pathways. Understanding the mechanism matters because it determines who a given compound might benefit — and what the risks are.

GLP-1 Receptor Agonism (appetite and satiety) The most validated mechanism. GLP-1 is a gut hormone that slows gastric emptying, increases insulin secretion, and — critically — acts on the hypothalamus to reduce appetite. Synthetic GLP-1 analogs amplify and extend this signal, producing caloric reduction through appetite suppression rather than stimulant-style thermogenesis.

GH Secretagogue Activity (fat mobilization, body composition) Growth hormone-releasing peptides (GHRPs) and GHRH analogs stimulate GH release. GH is lipolytic — it preferentially mobilizes visceral and subcutaneous fat while preserving lean mass. This makes GH secretagogues useful for body composition change, though they’re not caloric-restriction substitutes.

Direct Lipolytic Activity (fat cell targeting) Some peptides act directly on adipocytes. AOD-9604, the C-terminal fragment of growth hormone, binds fat cell receptors and directly stimulates lipolysis without the anabolic effects of full HGH.

Metabolic Enzyme Inhibition (NAD+ / NNMT pathway) Newer compounds like 5-Amino-1MQ work by blocking NNMT, an enzyme that degrades NAD+ precursors. In preclinical models, this creates a metabolic state resembling caloric restriction — increased fat oxidation, improved insulin sensitivity, preserved muscle mass.

---

Tier 1: FDA-Approved Peptides With Strong Clinical Evidence

Semaglutide (Ozempic / Wegovy)

The current standard for GLP-1 therapy. The STEP trials established 15–17% body weight reduction at 2.4 mg weekly — numbers no oral medication had previously approached. The SELECT cardiovascular outcomes trial added a 20% reduction in MACE in non-diabetic overweight patients, confirming benefit beyond the scale.

Mechanism: GLP-1 receptor agonist (weekly SC injection or daily oral)
Weight loss: 15–17% body weight over 68 weeks
Best for: Patients where appetite suppression and cardiovascular benefit are the primary goals
Limitation: GI side effects during titration; compounding now prohibited following shortage resolution

→ See full semaglutide monograph

Tirzepatide (Mounjaro / Zepbound)

The successor. Tirzepatide adds GIP receptor agonism to GLP-1 agonism, and the combination appears synergistic. SURMOUNT-1 showed 20.9% average body weight reduction at the 15 mg dose — roughly one-third better than semaglutide head-to-head. SURMOUNT-2 and SURMOUNT-3 confirmed durability.

Mechanism: Dual GLP-1/GIP receptor agonist (weekly SC injection)
Weight loss: 15–22.5% body weight depending on dose
Best for: Patients who need maximum weight loss efficacy; those with concurrent T2D
Limitation: Higher cost; cardiovascular outcomes trial still ongoing

→ See full tirzepatide monograph

Tesamorelin (Egrifta)

FDA-approved specifically for visceral adiposity reduction in HIV-associated lipodystrophy. Tesamorelin is a GHRH analog — it stimulates GH release, which preferentially targets visceral fat. Phase II trials are evaluating it for NASH in the general population, which would broaden its approved use significantly.

Mechanism: GHRH analog → GH pulse stimulation → visceral lipolysis
Weight loss: Not a body weight reducer; specific to visceral fat reduction
Best for: Visceral adiposity, metabolic syndrome, practitioners seeking a GH mechanism with an approved track record
Limitation: Narrow approved indication; off-label use requires informed consent

→ See full tesamorelin monograph

---

Tier 2: Restricted Peptides With Moderate Evidence

CJC-1295 + Ipamorelin Stack

These are the most commonly prescribed GH secretagogues outside of tesamorelin. CJC-1295 is a GHRH analog (long-acting); ipamorelin is a selective GHRP. Combined, they produce synergistic GH release. Human pharmacokinetic trials exist for both. The weight loss data is indirect — practitioners observe body composition changes (fat reduction, muscle preservation) consistent with elevated GH, but purpose-designed weight loss trials are absent.

FDA restricted compounding of both following 2023 actions. Access has narrowed significantly since.

Mechanism: GHRH analog + GHRP → GH secretion → lipolysis
Evidence level: Moderate (PK/PD data; indirect body composition evidence)
Regulatory status: Restricted — not currently available through licensed 503A compounding
Best for: Body composition recomposition, not primary obesity treatment

→ CJC-1295 monograph | Ipamorelin monograph

---

Tier 3: Research-Stage Compounds — Preclinical Evidence Only

AOD-9604

AOD-9604 is the C-terminal GH fragment (amino acids 177–191), modified for stability. It completed a Phase 3 obesity trial — which did not hit primary endpoints on weight loss — but animal data on direct lipolysis remains interesting. It subsequently received FDA GRAS status in the context of food additives, which is a narrow and often-misrepresented finding.

The compound is not FDA-approved, not on the 503A list, and the Phase 3 failure is a significant data point that the research peptide market consistently minimizes.

Mechanism: Direct adipocyte receptor binding → lipolysis (without HGH anabolic effects)
Evidence level: Preliminary — strong animal data, Phase 3 human trial did not reach primary endpoint
Regulatory status: Research-only
Bottom line: The mechanism is real; the human efficacy evidence is not there yet

→ See full AOD-9604 monograph

5-Amino-1MQ

5-Amino-1MQ is a small-molecule NNMT inhibitor, technically a methylquinolinium compound rather than a peptide in the traditional sense. Preclinical data in rodent models shows significant fat mass reduction and preserved lean mass without caloric restriction. The NAD+ pathway mechanism is biologically plausible and generates legitimate scientific interest.

Human data: none yet. Dosing in humans is extrapolated from animal studies. It’s being used clinically by some longevity practitioners, but any practitioner recommending it should be clear that they’re operating outside any established evidence base.

Mechanism: NNMT inhibition → NAD+ preservation → metabolic shift toward fat oxidation
Evidence level: Preliminary — preclinical only
Regulatory status: Research-only
Bottom line: Plausible mechanism, no human data, use with eyes open

→ See full 5-Amino-1MQ monograph

---

What This Looks Like in Practice

For primary obesity treatment: GLP-1 receptor agonists are the evidence-backed choice. Semaglutide or tirzepatide, depending on the patient profile. Nothing else in this space approaches their magnitude of effect.

For body composition (fat loss with muscle preservation): GH secretagogues — tesamorelin (approved) or CJC-1295/ipamorelin (where legally accessible) — address the visceral/subcutaneous fat compartment while preserving lean mass. Different mechanism, different patient.

For the research-curious patient: AOD-9604 and 5-Amino-1MQ have plausible biology and limited human risk signals. But both require an honest informed consent conversation: the human efficacy data is not there. “I’m prescribing this because the mechanism is interesting and the risk profile appears low” is a defensible position. “This is proven to burn fat” is not.

---

Matching Mechanism to Patient

Primary obesity, significant BMI: GLP-1 receptor agonists are the answer. The magnitude of effect is unmatched and the evidence is unambiguous. Tirzepatide for maximum efficacy; semaglutide where CV outcomes data matters now.

Metabolic syndrome, visceral adiposity, normal or near-normal BMI: Tesamorelin (if you need an approved track record) or GH secretagogues (where accessible) are mechanistically better suited. These patients don’t need appetite suppression — they need preferential visceral fat mobilization.

Body recomposition — losing fat while preserving or building muscle: GH secretagogues over GLP-1s. GLP-1-driven weight loss produces meaningful lean mass loss alongside fat loss. GH secretagogues preserve lean tissue.

Research-motivated patients, longevity-focused practice: AOD-9604 and 5-Amino-1MQ have plausible biology and appear low-risk. Informed consent is the standard — patients need to understand they’re participating in n=1 experiments with no established human efficacy baseline.

---

What Practitioners Often Miss

GLP-1s don’t directly burn fat. They reduce caloric intake. The fat loss is downstream of behavioral change driven by pharmacology. This matters clinically: patients who compensate with liquid calories, or whose appetite suppression fades at plateau, will not get the full STEP trial result.

GH secretagogues don’t produce dramatic weight loss. If a patient’s primary complaint is “I weigh too much,” GH secretagogues aren’t the first-line answer. If the complaint is “my waist measurement is increasing despite normal weight” or “I’m losing muscle,” that’s the right patient.

The research peptide market conflates mechanism with evidence. A compound having a plausible fat-burning mechanism is not the same as it being proven to burn fat in humans. AOD-9604 is the case study: the mechanism is real, the Phase 3 missed, and the compound is still marketed as though the mechanism is the proof.

---

2026 Pipeline: Next-Wave Weight Loss Compounds

Two compounds are worth tracking as the next wave of evidence-supported options:

Retatrutide (Eli Lilly, Phase 3) Triple agonist: GLP-1 + GIP + glucagon receptors. The glucagon receptor component adds direct fat mobilization that the dual GLP-1/GIP mechanism doesn’t fully capture. Phase 2 data showed ~24% body weight reduction at 12 mg weekly — the highest efficacy signal of any compound tested at Phase 2. The TRIUMPH Phase 3 program is running now; approval expected 2026–2027 if data holds.

Cagrilintide / CagriSema (Novo Nordisk, Phase 3) Cagrilintide is a long-acting amylin analog that works through a complementary mechanism to semaglutide — amylin signaling slows gastric emptying and reduces glucagon independently of GLP-1. The CagriSema co-formulation (cagrilintide + semaglutide in a single injection) is showing 22–25%+ weight loss in the REDEFINE trials. If approved, it would challenge tirzepatide’s position at the efficacy ceiling.

Both compounds represent incremental improvements in an already-effective class, not paradigm shifts. The compounds worth watching in the earlier research stage — if you want a genuinely different mechanism — remain 5-Amino-1MQ and the NNMT inhibitor class.

---

What to Watch

The July 2026 FDA advisory panel reviewing seven peptides — including compounds in the GH secretagogue class — could meaningfully change the regulatory landscape. If that panel moves any compound toward the 503A list, access will broaden. If it goes the other way, it narrows further.

Retatrutide (GLP-1/GIP/glucagon triple agonist, Phase 3) is showing 24%+ weight loss in early data and will likely reshape the GLP-1 class again within 12–18 months.

→ FDA Advisory Panel Preview: July 2026